<DOC>
	<DOCNO>NCT01254370</DOCNO>
	<brief_summary>The purpose study compare : - effect Catioprost® Travatan Z® ocular surface disease ( OSD ) subject glaucoma ocular hypertension ocular surface disease . - intraocular pressure ( IOP ) lower effect safety Catioprost® Travatan Z® subject glaucoma ocular hypertension ocular surface disease .</brief_summary>
	<brief_title>Safety Efficacy Study Catioprost® ( Unpreserved Latanoprost 0.005 % Emulsion ) Compared Travatan Z® Treat Glaucoma Ocular Surface Disease</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Glaucoma</mesh_term>
	<mesh_term>Ocular Hypertension</mesh_term>
	<mesh_term>Latanoprost</mesh_term>
	<mesh_term>Travoprost</mesh_term>
	<criteria>Be least 18 year age Visit 1 ( IOP Screening ) , either sex race ethnicity . Be willing able provide write informed consent prior study procedure perform . Be willing able follow instruction attend study visit . Have document diagnosis ocular hypertension , open angle glaucoma ( without pseudoexfoliation pigment dispersion component ) chronic angle closure glaucoma patent iridotomy require treatment ocular hypertensive therapy study eye . Agree submit pregnancy test Visit 1 Visit 4 , childbearing potential . Agree use acceptable method contraception duration study childbearing potential . Acceptable method birth control include : spermicide barrier , oral , transdermal , injectable , implantable contraception , IUD , abstinence , surgical sterilization partner . Female subject childbearing potential hysterectomy , bilateral oophorectomy , bilateral tubal ligation , postmenopausal least 12 month . Have know sensitivity poor tolerance latanoprost travoprost component study medication . Have form glaucoma open angle glaucoma ( without pigment dispersion pseudoexfoliation component ) , ocular hypertension chronic angle closure glaucoma patent iridotomy either eye . Have IOP time point Screening Baseline visit ( Visits 1 2 ) &gt; 34 mmHg either eye . Be currently pregnant , nursing , plan pregnancy study period ; woman positive pregnancy test . Have history significant ocular condition ( ) either eye would contraindicate use latanoprost travoprost , might affect study conduct interpretation study result . Have abnormality prevent reliable Goldmann applanation tonometry either eye . Have previously nonresponsive prostaglandin analog therapy reduction IOP . Have prior ( within 30 day Visit 1 ) anticipate concurrent use investigational drug device study period . Have condition situation , Investigator 's opinion , may put subject increase risk , confound study data , interfere significantly subject 's study participation .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>